AGIO vs SRPT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AGIO · Agios Pharmaceuticals$29.41 ▲ 4.03%
SRPT · Sarepta Therapeutics$17.82 ▲ 1.42%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AGIO -28.9%
- SRPT +3.2%
Head to head
| Metric | AGIO | SRPT |
|---|---|---|
| Price | $29.41 | $17.82 |
| Change today | ▲ 4.03% | ▲ 1.42% |
| Market cap | $1.76B | $1.91B |
| Return, 3 months | -9.8% | +3.7% |
| Return, year to date | +8.0% | -17.2% |
| Return, 1 year | -27.7% | +1.1% |
| P/E (TTM) | – | – |
| P/B | 1.8 | 1.2 |
| P/E percentile vs own 5y | 59th | 47th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +259.3% | -34.3% |
| Net profit growth (YoY) | +10.1% | -102.5% |
| Gross margin | 92.0% | 59.1% |
| Operating margin | -466.8% | -3.2% |
| Net margin | -418.2% | -6.9% |
| Return on equity | -34.3% | -9.5% |
| Analyst target vs. price | +53.7% | +22.3% |
| Analyst buy share | 83% | 19% |
| RSI (14) | 38 | 46 |
| 30-day volatility | 81.4% | 54.0% |
| Max drawdown, 1 year | -50.9% | -39.2% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SRPT is the largest of the group by market value.
- SRPT has returned the most over the past year.
- AGIO is growing revenue fastest.
- SRPT keeps the most profit per dollar of sales.
- SRPT has been the calmest stock over the last 30 days.